U.S. markets closed
  • S&P Futures

    3,836.50
    +17.25 (+0.45%)
     
  • Dow Futures

    31,905.00
    +129.00 (+0.41%)
     
  • Nasdaq Futures

    12,384.75
    +87.50 (+0.71%)
     
  • Russell 2000 Futures

    2,209.50
    +8.70 (+0.40%)
     
  • Crude Oil

    65.35
    +0.30 (+0.46%)
     
  • Gold

    1,683.70
    +5.70 (+0.34%)
     
  • Silver

    25.28
    +0.01 (+0.04%)
     
  • EUR/USD

    1.1854
    +0.0001 (+0.01%)
     
  • 10-Yr Bond

    1.5960
    +0.0420 (+2.70%)
     
  • Vix

    25.47
    +0.81 (+3.28%)
     
  • GBP/USD

    1.3829
    +0.0007 (+0.05%)
     
  • USD/JPY

    109.1640
    +0.2630 (+0.24%)
     
  • BTC-USD

    53,454.77
    +2,001.73 (+3.89%)
     
  • CMC Crypto 200

    1,079.32
    +55.11 (+5.38%)
     
  • FTSE 100

    6,719.13
    +88.61 (+1.34%)
     
  • Nikkei 225

    28,833.04
    +89.79 (+0.31%)
     

Veracyte to Present at the Jefferies Virtual Healthcare Conference

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Veracyte, Inc. (Nasdaq: VCYT) announced today that Bonnie H. Anderson, chairman and chief executive officer, is scheduled to present at the Jefferies Virtual Healthcare Conference on Wednesday, June 3, 2020 at 3:30 p.m. Eastern Time.

The link to the live audio webcast of the company’s presentation will be available by visiting Veracyte’s website at https://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.

About Veracyte

Veracyte (Nasdaq: VCYT) is a global genomic diagnostics company that improves patient care by providing answers to clinical questions, informing diagnosis and treatment decisions throughout the patient journey in cancer and other diseases. The company’s growing menu of genomic tests leverage advances in genomic science and technology, enabling patients to avoid risky, costly diagnostic procedures and quicken time to appropriate treatment. The company’s tests in thyroid cancer, lung cancer, breast cancer and idiopathic pulmonary fibrosis are available to patients and its lymphoma subtyping test is in development. With Veracyte’s exclusive global license to a best-in-class diagnostics instrument platform, the company is positioned to deliver its tests to patients worldwide. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com and follow the company on Twitter (@veracyte).

Veracyte, Afirma, Percepta, Envisia, Prosigna, LymphMark, nCounter and the Veracyte logo are trademarks of Veracyte, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200521005171/en/

Contacts

Investor and Media Contact:
Tracy Morris
Vice President of Corporate Communications
& Investor Relations
650-380-4413
tracy.morris@veracyte.com